$AQST
Aquestive Therapeutics, Inc. Stock $aqst

$aqst Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024009010 Filed on March 05, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$12.05M	$13.21M	$50.58M
YoY Change	8.25%	23.63%	6.09%
Cost Of Revenue	$4.389M	$4.679M	$20.83M
YoY Change	-7.35%	-11.8%	7.45%
Gross Profit	$7.664M	$8.527M	$29.75M
YoY Change	19.81%	58.58%	5.15%
Gross Profit Margin	63.59%	64.57%	58.82%
Selling, General & Admin	$10.69M	$9.550M	$31.75M
YoY Change	43.38%	-19.15%	-39.96%
% of Gross Profit	139.47%	112.0%	106.72%
Research & Development	$5.932M	$2.888M	$13.10M
YoY Change	67.24%	-32.49%	-25.04%
% of Gross Profit	77.4%	33.87%	44.04%
Depreciation & Amortization	$168.0K	$467.0K	$1.153M
YoY Change	-41.26%	17.63%	-49.21%
% of Gross Profit	2.19%	5.48%	3.88%
Operating Expenses	$16.62M	$12.44M	$44.85M
YoY Change	51.07%	-22.7%	-36.25%
Operating Profit	-$8.957M	-$3.911M	-$15.10M
YoY Change	94.51%	-63.49%	-64.1%
Interest Expense	$2.784M	-$2.108M	$6.337M
YoY Change	94.01%	28.62%	-151.34%
% of Operating Profit
Other Income/Expense, Net	-$1.416M	-$962.0K	-$1.125M
YoY Change
Pretax Income	-$12.83M	-$8.010M	-$7.625M
YoY Change	-259.0%	-35.15%	-85.99%
Income Tax	$0.00	$101.0K	$245.0K
% Of Pretax Income
Net Earnings	-$12.83M	-$8.111M	-$7.870M
YoY Change	-259.0%	-34.33%	-85.54%
Net Earnings / Revenue	-106.43%	-61.42%	-15.56%
Basic Earnings Per Share	-$0.17		-$0.13
Diluted Earnings Per Share	-$0.17	-$0.12	-$0.13
COMMON SHARES
Basic Shares Outstanding	73.30M shares	66.77M shares	61.26M shares
Diluted Shares Outstanding	73.61M shares		61.26M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$95.20M	$23.87M	$23.87M
YoY Change	254.14%	-12.47%	-12.47%
Cash & Equivalents	$95.20M	$23.87M	$23.87M
Short-Term Investments
Other Short-Term Assets	$2.121M	$1.854M	$1.854M
YoY Change	-7.46%	-13.0%	-13.0%
Inventory	$7.734M	$6.769M	$6.769M
Prepaid Expenses
Receivables	$8.324M	$8.471M	$8.471M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$113.4M	$40.97M	$40.97M
YoY Change	159.41%	2.7%	2.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.046M	$4.179M	$9.736M
YoY Change	6.08%	-47.11%	23.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.417M	$5.438M	$1.438M
YoY Change	-16.47%	-15.7%	-77.71%
Total Long-Term Assets	$16.14M	$16.45M	$16.45M
YoY Change	-8.16%	4.21%	4.21%
TOTAL ASSETS
Total Short-Term Assets	$113.4M	$40.97M	$40.97M
Total Long-Term Assets	$16.14M	$16.45M	$16.45M
Total Assets	$129.5M	$57.42M	$57.42M
YoY Change	111.35%	3.13%	3.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.52M	$8.926M	$8.926M
YoY Change	-15.41%	-10.26%	-10.26%
Accrued Expenses	$4.637M	$6.497M	$6.887M
YoY Change	2.86%	-22.41%	-17.75%
Deferred Revenue	$1.551M	$1.551M
YoY Change	-67.45%	2.51%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$23.00K	$22.00K	$22.00K
YoY Change	-99.87%	-99.88%	-99.88%
Total Short-Term Liabilities	$18.06M	$18.31M	$18.31M
YoY Change	-55.28%	-53.86%	-53.86%
LONG-TERM LIABILITIES
Long-Term Debt	$28.76M	$27.51M	$27.51M
YoY Change	14.14%	-17.76%	-17.76%
Other Long-Term Liabilities	$2.021M	$2.016M	$118.1M
YoY Change	-1.85%	-98.01%	16.8%
Total Long-Term Liabilities	$2.021M	$2.016M	$145.6M
YoY Change	-1.85%	-98.5%	8.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.06M	$18.31M	$18.31M
Total Long-Term Liabilities	$2.021M	$2.016M	$145.6M
Total Liabilities	$165.8M	$163.9M	$163.9M
YoY Change	-2.75%	-5.93%	-5.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$331.9M	-$319.1M
YoY Change	9.49%	2.53%
Common Stock	$90.00K	$69.00K
YoY Change	60.71%	25.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$36.30M	-$106.5M	-$106.5M
YoY Change
Total Liabilities & Shareholders Equity	$129.5M	$57.42M	$57.42M
YoY Change	111.35%	3.13%	3.13%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$12.83M	-$8.111M	-$7.870M
YoY Change	-259.0%	-34.33%	-85.54%
Depreciation, Depletion And Amortization	$168.0K	$467.0K	$1.153M
YoY Change	-41.26%	17.63%	-49.21%
Cash From Operating Activities	-$10.38M	-$4.942M	-$6.380M
YoY Change	-217.79%	-158.51%	-34.82%
INVESTING ACTIVITIES
Capital Expenditures	$29.00K	$16.00K	$995.0K
YoY Change	1350.0%	-38.46%	-2.83%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$29.00K	-$16.00K	-$995.0K
YoY Change	1350.0%	-38.46%	-60.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$81.74M	3.913M	$3.974M
YoY Change	-988.01%	1818.14%	-65.63%
NET CHANGE
Cash From Operating Activities	-$10.38M	-4.942M	-$6.380M
Cash From Investing Activities	-$29.00K	-16.00K	-$995.0K
Cash From Financing Activities	$81.74M	3.913M	$3.974M
Net Change In Cash	$71.33M	-1.045M	-$3.401M
YoY Change	-18342.46%	-112.12%	352.86%
FREE CASH FLOW
Cash From Operating Activities	-$10.38M	-$4.942M	-$6.380M
Capital Expenditures	$29.00K	$16.00K	$995.0K
Free Cash Flow	-$10.41M	-$4.958M	-$7.375M
YoY Change	-218.14%	-158.88%	-31.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Local Phone Number LocalPhoneNumber	941-1900
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	AQST
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	aqst	Accounts Receivable Allowances Credits And Payments AccountsReceivableAllowancesCreditsAndPayments	87000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001398733
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q4	aqst	Royalty Obligation Term RoyaltyObligationTerm	P8Y
CY2023Q4	aqst	Royalty Obligation Term RoyaltyObligationTerm	P8Y
CY2023	us-gaap	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38599
CY2023	dei	Entity Registrant Name EntityRegistrantName	Aquestive Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3827296
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	30 Technology Drive
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Warren
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07059
CY2023	dei	City Area Code CityAreaCode	908
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	82700000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73301201	shares
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2034000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	163905000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	175624000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68533085	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68533085	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54827734	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54827734	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	69000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	55000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	212521000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	192598000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-319077000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-311207000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-106487000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-118554000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57418000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57070000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50583000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47680000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	20831000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	19386000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13104000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17481000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31750000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	52879000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	65685000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	89746000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-15102000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-42066000	usd
CY2023	us-gaap	Interest Expense InterestExpense	6337000	usd
CY2022	us-gaap	Interest Expense InterestExpense	6552000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	905000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	245000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7870000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54410000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7870000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54410000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023	dei	Auditor Location AuditorLocation	Short Hills, New Jersey
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23872000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27273000	usd
CY2023Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	8471000	usd
CY2022Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	4704000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	6769000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5780000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1854000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2131000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	40966000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	39888000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4179000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4085000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5557000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5211000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1278000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1435000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5438000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6451000	usd
CY2023Q4	us-gaap	Assets Assets	57418000	usd
CY2022Q4	us-gaap	Assets Assets	57070000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8926000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9946000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6497000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7967000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	390000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	255000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1551000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1513000	usd
CY2023Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	922000	usd
CY2022Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1147000	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	22000	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	18700000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18308000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	39528000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	27508000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	33448000	usd
CY2023Q4	aqst	Royalty Obligation Liability RoyaltyObligationLiability	14761000	usd
CY2022Q4	aqst	Royalty Obligation Liability RoyaltyObligationLiability	0	usd
CY2023Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	63568000	usd
CY2022Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	64112000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5399000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5085000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	32345000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	31417000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2016000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2034000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	163905000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	175624000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68533085	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68533085	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54827734	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54827734	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	69000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	55000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	212521000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	192598000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-319077000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-311207000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-106487000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-118554000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57418000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50583000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47680000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	20831000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	19386000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13104000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17481000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31750000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	52879000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	65685000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	89746000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-15102000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-42066000	usd
CY2023	us-gaap	Interest Expense InterestExpense	6337000	usd
CY2022	us-gaap	Interest Expense InterestExpense	6552000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	905000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2022	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	5891000	usd
CY2023	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	16321000	usd
CY2022	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	99000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1382000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7625000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54410000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	245000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7870000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54410000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7870000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54410000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.12
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61255864	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61255864	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.12
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61255864	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61255864	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48734377	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48734377	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-82134000	usd
CY2022	aqst	Adjustments To Additional Paid In Capital Fair Value Of Warrants Issued AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantsIssued	5874000	usd
CY2022	aqst	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	0	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4196000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-289000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	34000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-3000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4371000	usd
CY2022	us-gaap	Stockholders Equity Other StockholdersEquityOther	-2000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54410000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-118554000	usd
CY2023	aqst	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	8342000	usd
CY2023	aqst	Adjustments To Additional Paid In Capital Warrant Exercised AdjustmentsToAdditionalPaidInCapitalWarrantExercised	-35000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9464000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-552000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	66000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-11000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2662000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2023	us-gaap	Stockholders Equity Other StockholdersEquityOther	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7870000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-106487000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7870000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54410000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1345000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2387000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2689000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4381000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1972000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	215000	usd
CY2023	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	0	usd
CY2022	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	5683000	usd
CY2023	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-1029000	usd
CY2022	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	204000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	52000	usd
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	3073000	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-7352000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	989000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1743000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1290000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1399000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1020000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1633000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2382000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	966000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	25043000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48734377	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48734377	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-82134000	usd
CY2022	aqst	Adjustments To Additional Paid In Capital Fair Value Of Warrants Issued AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantsIssued	5874000	usd
CY2022	aqst	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	0	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4196000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-289000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	34000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-3000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4371000	usd
CY2022	us-gaap	Stockholders Equity Other StockholdersEquityOther	-2000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54410000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-118554000	usd
CY2023	aqst	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	8342000	usd
CY2023	aqst	Adjustments To Additional Paid In Capital Warrant Exercised AdjustmentsToAdditionalPaidInCapitalWarrantExercised	-35000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9464000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-552000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	66000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-11000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2662000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7870000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-106487000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7870000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54410000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1345000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2387000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2689000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4381000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1972000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	215000	usd
CY2023	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	0	usd
CY2022	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	5683000	usd
CY2023	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-1029000	usd
CY2022	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	204000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	52000	usd
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	3073000	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-7352000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	989000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1743000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1290000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1399000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1020000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1633000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2515000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2382000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	966000	usd
CY2023	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	675000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6380000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9819000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	995000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1024000	usd
CY2023	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	675000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6380000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9819000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	995000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1024000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1500000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-995000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2524000	usd
CY2023	aqst	Proceeds From Issuance Of Public Offering Issuance Of Warrants And Warrant Exercises ProceedsFromIssuanceOfPublicOfferingIssuanceOfWarrantsAndWarrantExercises	8912000	usd
CY2022	aqst	Proceeds From Issuance Of Public Offering Issuance Of Warrants And Warrant Exercises ProceedsFromIssuanceOfPublicOfferingIssuanceOfWarrantsAndWarrantExercises	3907000	usd
CY2023	aqst	Proceeds From Issuance Private Offering ProceedsFromIssuancePrivateOffering	0	usd
CY2022	aqst	Proceeds From Issuance Private Offering ProceedsFromIssuancePrivateOffering	9679000	usd
CY2023	aqst	Proceeds From Exercise Of Warrants Net ProceedsFromExerciseOfWarrantsNet	8307000	usd
CY2022	aqst	Proceeds From Exercise Of Warrants Net ProceedsFromExerciseOfWarrantsNet	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	39000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	34000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	31144000	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2023	aqst	Proceeds From Issuance Of Royalty Rights Agreements ProceedsFromIssuanceOfRoyaltyRightsAgreements	13856000	usd
CY2022	aqst	Proceeds From Issuance Of Royalty Rights Agreements ProceedsFromIssuanceOfRoyaltyRightsAgreements	0	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	51529000	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	4643000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2023	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2102000	usd
CY2022	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2025000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	11000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3974000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11592000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3401000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-751000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27273000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28024000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23872000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27273000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	4602000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	6436000	usd
CY2023	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation and Principles of Consolidation<div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with GAAP in the United States of America, and in accordance with the rules and regulations of the SEC. The accounts of wholly owned subsidiaries are included in the consolidated financial statements. Other than corporate formation activities, no such subsidiaries have conducted any commercial, developmental or operational activities and none have customers or vendors. Certain reclassifications were made to conform to the current year presentation.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the ASC and ASU of FASB.</span></div>
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1500000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-995000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2524000	usd
CY2023	aqst	Proceeds From Issuance Of Public Offering Issuance Of Warrants And Warrant Exercises ProceedsFromIssuanceOfPublicOfferingIssuanceOfWarrantsAndWarrantExercises	8912000	usd
CY2022	aqst	Proceeds From Issuance Of Public Offering Issuance Of Warrants And Warrant Exercises ProceedsFromIssuanceOfPublicOfferingIssuanceOfWarrantsAndWarrantExercises	3907000	usd
CY2023	aqst	Proceeds From Issuance Private Offering ProceedsFromIssuancePrivateOffering	0	usd
CY2022	aqst	Proceeds From Issuance Private Offering ProceedsFromIssuancePrivateOffering	9679000	usd
CY2023	aqst	Proceeds From Exercise Of Warrants Net ProceedsFromExerciseOfWarrantsNet	8307000	usd
CY2022	aqst	Proceeds From Exercise Of Warrants Net ProceedsFromExerciseOfWarrantsNet	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	39000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	34000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	31144000	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2023	aqst	Proceeds From Issuance Of Royalty Rights Agreements ProceedsFromIssuanceOfRoyaltyRightsAgreements	13856000	usd
CY2022	aqst	Proceeds From Issuance Of Royalty Rights Agreements ProceedsFromIssuanceOfRoyaltyRightsAgreements	0	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	51529000	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	4643000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2023	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2102000	usd
CY2022	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2025000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	11000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3974000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11592000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3401000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-751000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27273000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28024000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23872000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27273000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	4602000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	6436000	usd
CY2023	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation and Principles of Consolidation<div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with GAAP in the United States of America, and in accordance with the rules and regulations of the SEC. The accounts of wholly owned subsidiaries are included in the consolidated financial statements. Other than corporate formation activities, no such subsidiaries have conducted any commercial, developmental or operational activities and none have customers or vendors. Certain reclassifications were made to conform to the current year presentation.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the ASC and ASU of FASB.</span></div>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates and assumptions often involve assessments of matters that are inherently uncertain and accordingly actual results could differ from those estimates. Significant items subject to estimates and assumptions include those related to revenue recognition, inventory costs, allowances for rebates from proprietary product sales prior to out-licensing to Assertio, allowances for sales returns, the useful lives of fixed assets and the valuations of warrants issued, royalty obligations, sale of future revenues, share-based compensation, and contingencies.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div>Cash and cash equivalents are held by federally insured financial institutions that management believes are of high credit quality. The Company has not experienced any losses in such accounts and such amounts may exceed federally-insured limits of $250.
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates and assumptions often involve assessments of matters that are inherently uncertain and accordingly actual results could differ from those estimates. Significant items subject to estimates and assumptions include those related to revenue recognition, inventory costs, allowances for rebates from proprietary product sales prior to out-licensing to Assertio, allowances for sales returns, the useful lives of fixed assets and the valuations of warrants issued, royalty obligations, sale of future revenues, share-based compensation, and contingencies.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div>Cash and cash equivalents are held by federally insured financial institutions that management believes are of high credit quality. The Company has not experienced any losses in such accounts and such amounts may exceed federally-insured limits of $250.
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	216000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	aqst	Research And Development Project Duration ResearchAndDevelopmentProjectDuration	P3Y
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	216000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	aqst	Research And Development Project Duration ResearchAndDevelopmentProjectDuration	P3Y
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23872000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-319077000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23872000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-319077000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50583000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47680000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	5570000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	3274000	usd
CY2023Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2915000	usd
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2139000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2023Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	0	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	669000	usd
CY2023Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	8471000	usd
CY2022Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	4704000	usd
CY2023Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2915000	usd
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2139000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-26000	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	0	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-26000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50583000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50583000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47680000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	5570000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	3274000	usd
CY2023Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2915000	usd
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2139000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2023Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	0	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	669000	usd
CY2023Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	8471000	usd
CY2022Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	4704000	usd
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2139000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-26000	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	0	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-26000	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	669000	usd
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	605000	usd
CY2023	aqst	Accounts Receivable Allowances Provision Related To Sales AccountsReceivableAllowancesProvisionRelatedToSales	0	usd
CY2022	aqst	Accounts Receivable Allowances Provision Related To Sales AccountsReceivableAllowancesProvisionRelatedToSales	1365000	usd
CY2022	aqst	Accounts Receivable Allowances Credits And Payments AccountsReceivableAllowancesCreditsAndPayments	1301000	usd
CY2023	aqst	Accounts Receivable Allowances Reclassifications AccountsReceivableAllowancesReclassifications	582000	usd
CY2022	aqst	Accounts Receivable Allowances Reclassifications AccountsReceivableAllowancesReclassifications	0	usd
CY2023Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	0	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	669000	usd
CY2023	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	0	usd
CY2023Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	0	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	645000	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	669000	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1012000	usd
CY2022Q2	aqst	Pro Rata Portion Of Target Bonus ProRataPortionOfTargetBonus	280000	usd
CY2022Q2	aqst	Cash Payment Representing90 Days Of Base Pay CashPaymentRepresenting90DaysOfBasePay	150000	usd
CY2022Q2	aqst	Days Of Base Pay DaysOfBasePay	90	d
CY2022Q2	aqst	Consulting Fee ConsultingFee	10000	usd
CY2023Q4	aqst	Royalty Obligation Term RoyaltyObligationTerm	P8Y
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2118000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1899000	usd
CY2022Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	2914000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1623000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	967000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5780000	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	669000	usd
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	605000	usd
CY2023	aqst	Accounts Receivable Allowances Provision Related To Sales AccountsReceivableAllowancesProvisionRelatedToSales	0	usd
CY2022	aqst	Accounts Receivable Allowances Provision Related To Sales AccountsReceivableAllowancesProvisionRelatedToSales	1365000	usd
CY2022	aqst	Accounts Receivable Allowances Credits And Payments AccountsReceivableAllowancesCreditsAndPayments	1301000	usd
CY2023	aqst	Accounts Receivable Allowances Reclassifications AccountsReceivableAllowancesReclassifications	582000	usd
CY2022	aqst	Accounts Receivable Allowances Reclassifications AccountsReceivableAllowancesReclassifications	0	usd
CY2023Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	0	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	669000	usd
CY2023	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	0	usd
CY2023Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	0	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	645000	usd
CY2022Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	669000	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1012000	usd
CY2022Q2	aqst	Pro Rata Portion Of Target Bonus ProRataPortionOfTargetBonus	280000	usd
CY2022Q2	aqst	Cash Payment Representing90 Days Of Base Pay CashPaymentRepresenting90DaysOfBasePay	150000	usd
CY2022Q2	aqst	Days Of Base Pay DaysOfBasePay	90	d
CY2022Q2	us-gaap	Severance Costs1 SeveranceCosts1	263000	usd
CY2022Q2	aqst	Number Of Installments NumberOfInstallments	3	installment
CY2022Q2	aqst	Severance Period SeverancePeriod	P18M
CY2022Q2	aqst	Coverage Duration CoverageDuration	P18M
CY2022Q2	aqst	Consulting Fee ConsultingFee	10000	usd
CY2023Q4	aqst	Royalty Obligation Term RoyaltyObligationTerm	P8Y
CY2023Q4	aqst	Royalty Obligation Term RoyaltyObligationTerm	P8Y
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2118000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1899000	usd
CY2023Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	3028000	usd
CY2022Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	2914000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1623000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	967000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	6769000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5780000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47063000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46048000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	42884000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41963000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4179000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4085000	usd
CY2023	us-gaap	Depreciation Depreciation	1153000	usd
CY2022	us-gaap	Depreciation Depreciation	2270000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	216000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	aqst	Number Of Leases NumberOfLeases	3	lease
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1745000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1753000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	447000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	449000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1230000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1266000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1300000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1328000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1162000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	3828000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10114000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4306000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5808000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4367000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4367000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47063000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46048000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	42884000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4179000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4085000	usd
CY2023	us-gaap	Depreciation Depreciation	1153000	usd
CY2022	us-gaap	Depreciation Depreciation	2270000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	216000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	aqst	Number Of Leases NumberOfLeases	3	lease
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1745000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1753000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	447000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	449000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1230000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1266000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1300000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1328000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1162000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	3828000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10114000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4306000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5808000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4367000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4367000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3089000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2932000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1278000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1435000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	157000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	157000	usd
CY2023	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P8Y1M6D
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	157000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	157000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	157000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	157000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	157000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	493000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1278000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3089000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2932000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1278000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1435000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	157000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	157000	usd
CY2023	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P8Y1M6D
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	157000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	157000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	157000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	157000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	157000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	493000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1278000	usd
CY2023Q4	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	4000000	usd
CY2022Q4	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	5000000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	1438000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	1451000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5438000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6451000	usd
CY2023	aqst	Number Of Guaranteed Royalty Payments NumberOfGuaranteedRoyaltyPayments	8	royalty_payment
CY2023Q4	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	4000000	usd
CY2022Q4	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	5000000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	1438000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	1451000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5438000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6451000	usd
CY2023	aqst	Number Of Guaranteed Royalty Payments NumberOfGuaranteedRoyaltyPayments	8	royalty_payment
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4202000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	337000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	322000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	645000	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1012000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1013000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	183000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	300000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	61000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6497000	usd
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2023	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	usd
CY2022Q4	aqst	Debt Instrument Number Of Notices Of Redemption DebtInstrumentNumberOfNoticesOfRedemption	2	notice
CY2023	aqst	Debt Instrument Number Of Payments Made DebtInstrumentNumberOfPaymentsMade	3	payment
CY2023Q4	aqst	Royalty Obligation Term RoyaltyObligationTerm	P8Y
CY2023Q4	aqst	Royalty Obligation Term RoyaltyObligationTerm	P8Y
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4202000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6389000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	337000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	322000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	645000	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1012000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1013000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	183000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	300000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	61000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6497000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7967000	usd
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2019Q3	aqst	Net Proceeds From Issuance Of Initial Notes Warrants And First Offer Rights NetProceedsFromIssuanceOfInitialNotesWarrantsAndFirstOfferRights	66082000	usd
CY2023	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	usd
CY2022Q4	aqst	Debt Instrument Number Of Notices Of Redemption DebtInstrumentNumberOfNoticesOfRedemption	2	notice
CY2023	aqst	Debt Instrument Number Of Payments Made DebtInstrumentNumberOfPaymentsMade	3	payment
CY2023Q4	aqst	Royalty Obligation Term RoyaltyObligationTerm	P8Y
CY2023Q4	aqst	Royalty Obligation Term RoyaltyObligationTerm	P8Y
CY2023Q4	aqst	Royalty Obligation Fair Value Allocated RoyaltyObligationFairValueAllocated	13856000	usd
CY2023Q4	aqst	Royalty Obligations Gross RoyaltyObligationsGross	56926000	usd
CY2023Q4	aqst	Royalty Obligation Fair Value Allocated RoyaltyObligationFairValueAllocated	13856000	usd
CY2023Q4	aqst	Royalty Obligation Interest Rate RoyaltyObligationInterestRate	0.0968
CY2023Q4	aqst	Royalty Obligation Fair Value Allocated RoyaltyObligationFairValueAllocated	13856000	usd
CY2023Q4	aqst	Royalty Obligation Unamortized Discount RoyaltyObligationUnamortizedDiscount	42165000	usd
CY2022Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	65259000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	220000	usd
CY2023	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	0	usd
CY2023Q4	aqst	Royalty Obligation Fair Value Allocated RoyaltyObligationFairValueAllocated	13856000	usd
CY2023Q4	aqst	Royalty Obligations Gross RoyaltyObligationsGross	56926000	usd
CY2023Q4	aqst	Royalty Obligation Fair Value Allocated RoyaltyObligationFairValueAllocated	13856000	usd
CY2023Q4	aqst	Royalty Obligation Interest Rate RoyaltyObligationInterestRate	0.0968
CY2023Q4	aqst	Royalty Obligation Fair Value Allocated RoyaltyObligationFairValueAllocated	13856000	usd
CY2023Q4	aqst	Royalty Obligation Unamortized Discount RoyaltyObligationUnamortizedDiscount	42165000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	173000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	27508000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	33448000	usd
CY2023Q4	aqst	Royalty Obligations Gross RoyaltyObligationsGross	56926000	usd
CY2023Q4	aqst	Royalty Obligation Unamortized Discount RoyaltyObligationUnamortizedDiscount	42165000	usd
CY2023Q4	aqst	Royalty Obligations Net RoyaltyObligationsNet	14761000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	9540000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	14535000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	20925000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	45000000	usd
CY2023	aqst	Proceeds From Exercise Of Warrants Net ProceedsFromExerciseOfWarrantsNet	8307000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	173000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	27508000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	33448000	usd
CY2023Q4	aqst	Royalty Obligations Gross RoyaltyObligationsGross	56926000	usd
CY2023Q4	aqst	Royalty Obligation Unamortized Discount RoyaltyObligationUnamortizedDiscount	42165000	usd
CY2023Q4	aqst	Royalty Obligations Net RoyaltyObligationsNet	14761000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	9540000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	14535000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	20925000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	45000000	usd
CY2023	aqst	Proceeds From Exercise Of Warrants Net ProceedsFromExerciseOfWarrantsNet	8307000	usd
CY2022Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	65259000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	220000	usd
CY2023	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	0	usd
CY2023Q4	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	922000	usd
CY2023Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	64490000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1800000	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4381000	usd
CY2023Q4	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	922000	usd
CY2023Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	64490000	usd
CY2022Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1989000	usd
CY2023	aqst	Asset Retirement Obligations Depreciation Expense AssetRetirementObligationsDepreciationExpense	7000	usd
CY2022	aqst	Asset Retirement Obligations Depreciation Expense AssetRetirementObligationsDepreciationExpense	25000	usd
CY2021Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1712000	usd
CY2022	us-gaap	Asset Retirement Obligation Liabilities Incurred AssetRetirementObligationLiabilitiesIncurred	110000	usd
CY2022	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	167000	usd
CY2022Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1989000	usd
CY2023	us-gaap	Asset Retirement Obligation Liabilities Incurred AssetRetirementObligationLiabilitiesIncurred	0	usd
CY2023	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	27000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7870000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54410000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61255864	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48734377	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
CY2022Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1989000	usd
CY2023	aqst	Asset Retirement Obligations Depreciation Expense AssetRetirementObligationsDepreciationExpense	7000	usd
CY2022	aqst	Asset Retirement Obligations Depreciation Expense AssetRetirementObligationsDepreciationExpense	25000	usd
CY2021Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1712000	usd
CY2022	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	167000	usd
CY2023	us-gaap	Asset Retirement Obligation Liabilities Incurred AssetRetirementObligationLiabilitiesIncurred	0	usd
CY2023	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	27000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7870000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54410000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61255864	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61255864	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48734377	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48734377	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.12
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1800000	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2689000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4381000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2689000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4381000	usd
CY2023	aqst	Inducement Equity Common Stock Options Granted Shares InducementEquityCommonStockOptionsGrantedShares	150000	shares
CY2023	aqst	Inducement Equity Common Stock Options Outstanding Shares InducementEquityCommonStockOptionsOutstandingShares	150000	shares
CY2023Q4	us-gaap	Share Price SharePrice	2.02
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	761000	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	815000	usd
CY2023	aqst	Inducement Equity Common Stock Options Outstanding Shares InducementEquityCommonStockOptionsOutstandingShares	150000	shares
CY2023Q4	us-gaap	Share Price SharePrice	2.02
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	761000	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	815000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	245000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	245000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	245000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	245000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	245000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	245000	usd
CY2023Q4	aqst	Deferred Tax Assets Accounts Receivable DeferredTaxAssetsAccountsReceivable	4000	usd
CY2022Q4	aqst	Deferred Tax Assets Accounts Receivable DeferredTaxAssetsAccountsReceivable	177000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	345000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	449000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	73000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1063000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27120000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	32197000	usd
CY2023Q4	aqst	Tax Cuts And Jobs Act Of2017 Deferred Tax Assets Interest Limitation TaxCutsAndJobsActOf2017DeferredTaxAssetsInterestLimitation	9880000	usd
CY2022Q4	aqst	Tax Cuts And Jobs Act Of2017 Deferred Tax Assets Interest Limitation TaxCutsAndJobsActOf2017DeferredTaxAssetsInterestLimitation	10667000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6529000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5813000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	7662000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2326000	usd
CY2023Q4	aqst	Deferred Tax Assets Sale Of Future Revenue DeferredTaxAssetsSaleOfFutureRevenue	16750000	usd
CY2022Q4	aqst	Deferred Tax Assets Sale Of Future Revenue DeferredTaxAssetsSaleOfFutureRevenue	17139000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2756000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2576000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4805000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5625000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	697000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1731000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5039000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3770000	usd
CY2023Q4	aqst	Deferred Tax Asset Royalty Obligations DeferredTaxAssetRoyaltyObligations	3520000	usd
CY2022Q4	aqst	Deferred Tax Asset Royalty Obligations DeferredTaxAssetRoyaltyObligations	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	58000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	82000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	84312000	usd
CY2023Q4	aqst	Deferred Tax Liabilities481a Adjustment DeferredTaxLiabilities481aAdjustment	193000	usd
CY2022Q4	aqst	Deferred Tax Liabilities481a Adjustment DeferredTaxLiabilities481aAdjustment	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	449000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	aqst	Deferred Tax Assets Accounts Receivable DeferredTaxAssetsAccountsReceivable	4000	usd
CY2022Q4	aqst	Deferred Tax Assets Accounts Receivable DeferredTaxAssetsAccountsReceivable	177000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	345000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	449000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	73000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1063000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27120000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	32197000	usd
CY2023Q4	aqst	Tax Cuts And Jobs Act Of2017 Deferred Tax Assets Interest Limitation TaxCutsAndJobsActOf2017DeferredTaxAssetsInterestLimitation	9880000	usd
CY2022Q4	aqst	Tax Cuts And Jobs Act Of2017 Deferred Tax Assets Interest Limitation TaxCutsAndJobsActOf2017DeferredTaxAssetsInterestLimitation	10667000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6529000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5813000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	7662000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2326000	usd
CY2023Q4	aqst	Deferred Tax Assets Sale Of Future Revenue DeferredTaxAssetsSaleOfFutureRevenue	16750000	usd
CY2022Q4	aqst	Deferred Tax Assets Sale Of Future Revenue DeferredTaxAssetsSaleOfFutureRevenue	17139000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2756000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2576000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4805000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5625000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	697000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	154000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1731000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5039000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3770000	usd
CY2023Q4	aqst	Deferred Tax Asset Royalty Obligations DeferredTaxAssetRoyaltyObligations	3520000	usd
CY2022Q4	aqst	Deferred Tax Asset Royalty Obligations DeferredTaxAssetRoyaltyObligations	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	58000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	82000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	84695000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	84312000	usd
CY2023Q4	aqst	Deferred Tax Liabilities481a Adjustment DeferredTaxLiabilities481aAdjustment	193000	usd
CY2022Q4	aqst	Deferred Tax Liabilities481a Adjustment DeferredTaxLiabilities481aAdjustment	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	449000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	524000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	642000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	524000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	84053000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	83788000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	84053000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	83788000	usd
CY2023Q4	aqst	Research And Development Costs Capitalized ResearchAndDevelopmentCostsCapitalized	12600000	usd
CY2022Q4	aqst	Research And Development Costs Capitalized ResearchAndDevelopmentCostsCapitalized	16600000	usd
CY2022Q4	aqst	Number Of Uncertain Tax Positions NumberOfUncertainTaxPositions	0	vestingperiod
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2023	aqst	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	-0.0043
CY2022	aqst	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	-0.0020
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0020
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	524000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	642000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	524000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	84053000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	83788000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	84053000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	83788000	usd
CY2023Q4	aqst	Research And Development Costs Capitalized ResearchAndDevelopmentCostsCapitalized	12600000	usd
CY2022Q4	aqst	Research And Development Costs Capitalized ResearchAndDevelopmentCostsCapitalized	16600000	usd
CY2022Q4	aqst	Number Of Uncertain Tax Positions NumberOfUncertainTaxPositions	0	vestingperiod
CY2023Q4	aqst	Number Of Uncertain Tax Positions NumberOfUncertainTaxPositions	0	vestingperiod
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0400
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0423
CY2023	aqst	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	-0.0043
CY2022	aqst	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	-0.0020
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0020
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2653
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2069
CY2023	aqst	Effective Income Tax Rate Reconciliation Tax Credit Return To Provision Percent EffectiveIncomeTaxRateReconciliationTaxCreditReturnToProvisionPercent	-0.0328
CY2022	aqst	Effective Income Tax Rate Reconciliation Tax Credit Return To Provision Percent EffectiveIncomeTaxRateReconciliationTaxCreditReturnToProvisionPercent	0.0011
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0178
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0467
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	-0.0380
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0322
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0002
CY2023Q4	aqst	Income Tax Examination Employee Retention Tax Credit Refund IncomeTaxExaminationEmployeeRetentionTaxCreditRefund	1250000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2653
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2069
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0467
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0322
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0002
CY2023Q4	aqst	Income Tax Examination Employee Retention Tax Credit Refund IncomeTaxExaminationEmployeeRetentionTaxCreditRefund	1250000	usd

Files In Submission

Name	View Source	Status
0001628280-24-009010-index-headers.html	Edgar Link	pending
0001628280-24-009010-index.html	Edgar Link	pending
0001628280-24-009010.txt	Edgar Link	pending
0001628280-24-009010-xbrl.zip	Edgar Link	pending
aqst-12312023xexhibit311.htm	Edgar Link	pending
aqst-12312023xexhibit312.htm	Edgar Link	pending
aqst-12312023xexhibit321.htm	Edgar Link	pending
aqst-12312023xexhibit322.htm	Edgar Link	pending
aqst-20231231.htm	Edgar Link	pending
aqst-20231231.xsd	Edgar Link	pending
aqst-20231231_g1.jpg	Edgar Link	pending
aqst-20231231_g2.jpg	Edgar Link	pending
aquestiveclawbackpolicy926.htm	Edgar Link	pending
ex231kpmgconsent123123.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pharmanovialsaamendment0.htm	Edgar Link	pending
pharmanovialsaamendment0001.jpg	Edgar Link	pending
pharmanovialsaamendment0002.jpg	Edgar Link	pending
pharmanovialsaamendment0003.jpg	Edgar Link	pending
pharmanovialsaamendment0004.jpg	Edgar Link	pending
pharmanovialsaamendment0005.jpg	Edgar Link	pending
pharmanovialsaamendment0006.jpg	Edgar Link	pending
pharmanovialsaamendment0007.jpg	Edgar Link	pending
pharmanovialsaamendment0008.jpg	Edgar Link	pending
pharmanovialsaamendment0009.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
aqst-20231231_lab.xml	Edgar Link	unprocessable
aqst-20231231_pre.xml	Edgar Link	unprocessable
aqst-20231231_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aqst-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
aqst-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AQST
Aquestive Therapeutics, Inc. Stock $aqst

2024 Q1 Form 10-K Financial Statement

#000162828024009010 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST Aquestive Therapeutics, Inc. Stock $aqst

2024 Q1 Form 10-K Financial Statement

#000162828024009010 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST
Aquestive Therapeutics, Inc. Stock $aqst